July 2007
The first wave of IT improvements solved some problems, but opportunities remain. Now it’s time for a more comprehensive approach.
Abstract
November 2006
Improving adherence to drug regimens can save lives and reduce health care costs.
Abstract
November 2006
Pharma companies should learn to segment the drugs in their
pipelines by risk.
Abstract
July 2006
Although late to offshoring, pharma companies stand to benefit at least as much as those in other industries.
Abstract
January 2006
Pharma's health will depend on a dose of IT to improve efficiency and innovation.
Abstract
September 2004
Focusing on the diversity within emerging markets can help pharma companies serve them profitably.
Abstract
August 2004
Pharma companies should reassess their mix of internally and externally developed products.
Abstract
August 2004
Efficacy isn’t everything.
Abstract
February 2004
As joint ventures become more complex, a division of labor is sometimes the key to successful partnerships.
Abstract
May 2003
The animal health industry will grow steadily over the next several years, providing solid if unspectacular profits for the pharma companies that own most of the businesses in it—but may now wish to divest them.
Abstract
May 2003
Despite restrictions on drug advertising in Japan, recent pilot campaigns suggest new ways for companies to reach out to patients.
Abstract
November 2002
In an industry in which many mergers have failed to create value, Fred Hassan has used them to take Pharmacia into the pharmaceutical big leagues. Here he explains how.
Abstract
November 2002
Pharmaceutical companies that license drugs too late are losing out on significant amounts of value.
Abstract
August 2002
Pharmaceutical companies have lost their focus on doctors. The key to higher sales is regaining it.
Abstract
June 2002
A shortfall in plant capacity threatens to slow down the delivery of protein-based therapeutics.
Abstract
May 2002
US pharma companies often miss their deadlines when testing new drugs. The use of marketing techniques to manage the recruitment of patients for clinical trials could speed things up considerably.
Abstract
December 2001
Governments and international organizations could reduce the financial risks borne by the developers and marketers of vaccines—and thereby make them cheaper and more plentiful.
Abstract
May 2001
Observers and analysts are looking forward to a profusion of innovative drugs, but they have paid far less attention to the business challenge of the "new biology."
Abstract
May 2001
Size can benefit drug manufacturers, but only if they manage it.
Abstract
February 2001
India’s drug companies will soon have to compete against global ones—by global rules.
Abstract
February 2001
Midsize companies need to think small—before the big ones do.
Abstract
August 2000
Swiss companies participated strongly in the pharmaceutical industry’s recent golden age of wealth creation, but it was their US rivals that set the benchmarks in stock value and performance. “Swiss drug makers: Facing the US giants” describes the moves the Swiss must make to secure their future.
Abstract
May 2000
The billions so far laid out on direct-to-consumer ads for prescription drugs have mostly failed to deliver. Yet the successes of a few companies show that failure is hardly inevitable.
Abstract
February 2000
Drug companies are more and more likely to license promising pharmaceutical compounds from other companies rather than develop their own. But does licensing pay?
Abstract
November 1999
Genetic technologies promise to transform the overall economics of developing and selling drugs. For companies in the pharmaceutical and biotechnology industries, the question isn't whether to invest but how soon.
Abstract
November 1996
Since price decontrol, the nominal growth rate has increased to 19 percent per year. Experience has led multinational pharmaceutical companies to cast a jaundiced eye on India’s basic research capabilities. They should reconsider.
Abstract
May 1996
Overcapacity still costs the industry almost half its value. What premiums? Savings can amount to 40 percent of an acquisition’s costs. Could all medical needs be met with 247 drugs?
Abstract